Aditum is Latin for access—our mission at Aditum Bio is to give patients access to medicines that may not otherwise be developed.
Aditum Bio is an investment firm focused on acquiring and developing biotechnology assets that will benefit patients.
Co-founded by industry veterans Joe Jimenez, former CEO of Novartis, Mark Fishman, former President of the Novartis Institutes for Biomedical Research, and Paul Sekhri, former CEO of Lycera, the firm works in collaboration with TrialSpark, a tech-enabled platform that conducts innovative clinical trials faster and at lower cost than traditional clinical development organizations (CROs).
Genetic, genomic and artificial intelligence have led to the discovery of new drug targets and therapeutic modalities; however, many drug candidates fail to be developed due to strategic decisions and high clinical trial expense.
Aditum Bio allows an alternative outlet for these discoveries as they advance into the clinic. We acquire these assets from biotechnology and pharma companies and develop them through Phase II utilizing TrialSpark as the innovative clinical research engine.